2018
Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort
Stahl M, Wei W, Montesinos P, Lengline E, Shallis R, Neukirchen J, Bhatt V, Sekeres M, Fathi A, Konig H, Luger S, Khan I, Roboz G, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Cruz E, Rabinovich E, Yoo B, Podoltsev N, Gore S, Zeidan A. Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. Blood 2018, 132: 4040. DOI: 10.1182/blood-2018-99-112974.Peer-Reviewed Original ResearchWhite blood cell countMedian overall survivalAcute myeloid leukemiaHematopoietic stem cell transplantIntensive chemotherapyTumor lysis syndromeOverall survivalTime of presentationComplete remissionAstex PharmaceuticalsSpeakers bureauPartial remissionTreatment patternsDaiichi SankyoJazz PharmaceuticalsCleveland Clinic Taussig Cancer InstituteJanssen PharmaceuticalsMedian white blood cell countHigher white blood cell countCelgene CorporationLong-term clinical outcomesAdvisory CommitteeImpact of leukapheresisIncomplete count recoveryMDS International Foundation
2015
Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial
Zeidan A, Zeidner J, Duffield A, Knaus H, Ferguson A, Sheldon K, DeZern A, Gojo I, Gore S, Streicher H, Luznik L, Smith B. Stabilization of Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: A Phase I Trial. Blood 2015, 126: 1666. DOI: 10.1182/blood.v126.23.1666.1666.Peer-Reviewed Original ResearchOverall survivalStable diseaseEnd of inductionMyelodysplastic syndromeFirst doseIpilimumab useMaintenance doseAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyDose levelsInternational Working Group 2006 criteriaMedian white blood cell countImmune checkpoint inhibition therapyImmune checkpoint inhibitor ipilimumabMedian absolute neutrophil countAllogeneic stem cell transplantationWhite blood cell countT cell receptor repertoireBM blast percentageCheckpoint inhibitor ipilimumabDose-escalation partGrade 3 irAEsOngoing stable diseasePhase 1b studyProlonged disease stabilizationTolerability of ipilimumabResults of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia
Zeidan A, Smith B, Carraway H, Gojo I, Sakoian S, Gore S, DeZern A. Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia. Blood 2015, 126: 2901. DOI: 10.1182/blood.v126.23.2901.2901.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeOverall hematologic response rateHigh-dose lenalidomideCycles of lenalidomideNon-hematologic toxicitiesAcute myeloid leukemiaOverall survivalTrilineage dysplasiaEntire cohortMyelodysplastic syndromePlatelet countGrade 3Myeloid leukemiaInternational Working Group 2006 criteriaJohns Hopkins Institutional Review BoardMedian white blood cell countSingle-arm phase II studyBone marrow blast percentageUnderwent bone marrow transplantationWhite blood cell countPhase 2 clinical trialHematologic response rateHigher risk MDSPoor-risk karyotypeCycles of therapy